Milestone Demonstrates Rapid Adoption of Next-Generation MR-Image Guided Radiation Therapy
CLEVELAND, March 27, 2018 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) announced that the company surpassed its 50th MRIdian MR image-guided radiation therapy system order during the first quarter of 2018 – a landmark achievement in the company’s history of bringing next-generation technology to the fight against cancer.
“The radiation oncology community has long awaited the integration of MR image-guidance with radiation delivery,” said Chris Raanes, president and CEO of ViewRay. “This breakthrough allows radiation oncologists to visualize soft tissue tumors in high definition, for the first time ever, while simultaneously and dynamically controlling radiation delivery to the patient. This remarkable achievement represents what we believe is the future of radiation therapy.”
ViewRay’s MRIdian is the only FDA-cleared and CE-marked MR-image guided radiation therapy system. Unlike conventional radiotherapy, the MRIdian system provides diagnostic-quality MR visualization of soft-tissue targets and surrounding organs. This recent technological advance enables daily on-table treatment plan adaptation to quickly and dynamically adjust for subtle anatomical changes that may occur, both during treatment delivery and throughout the course of treatment. Combined, these capabilities provide the potential for clinicians to improve targeting precision and thus deliver higher, and potentially more effective, radiation doses.
The 50th and subsequent 51st order were placed by RAD Technology Medical Systems, which provides revolutionary modular building systems for the healthcare industry including equipment and leasing options. RAD’s unique leasing options enable healthcare institutions to secure facilities and state-of-the-art technology, like MRIdian Linac, without lengthy capital procurement challenges and debt impairment.
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose-built to address specific challenges including beam distortion, skin toxicity, and other safety concerns, which may potentially occur when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements include improved targeting precision, the delivery of higher doses, and the potential for improved effectiveness. Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements. Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.